The role of percutaneous coronary intervention (PCI) in chronic total occlusions (CTOs) has long been framed more by technical progress than by evidence of clinical efficacy. Despite substantial advances in devices, techniques, and operator expertise, randomized data supporting CTO PCI for symptom relief have been limited by a lack of blinding, small sample sizes, high crossover, and confounding from concomitant non-CTO coronary artery disease. As a result, the true magnitude of symptomatic benefit attributable to CTO PCI has remained uncertain. This ambiguity is reflected in contemporary guidelines, with a Class IIb recommendation in the 2021 American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography Interventions revascularization guidelines and a Class IIa recommendation in the 2024 European Society of Cardiology chronic coronary syndrome guidelines.1,2
In this context, ORBITA-CTO represents an important advance. As the first double-blind, sham-controlled trial of CTO PCI, it was designed to isolate the physiologic effect of revascularization on symptoms. The investigators randomized 50 symptomatic patients with a CTO of low to moderate complexity (J-CTO ≤3) with evidence of ischemia in the subtended territory and no bystander coronary artery disease to PCI or a sham procedure following withdrawal of antianginal therapy.3 Symptoms were assessed daily using ORBITA-application, a smartphone web app, allowing detailed characterization of angina burden over time.4
The trial demonstrated a consistent and clinically meaningful reduction in angina and medication use in the PCI group as compared with the sham group. At 6 months, CTO PCI was associated with a reduction in daily angina frequency and blinded physician-assessed Canadian Cardiovascular Class (CCS), along with higher Seattle Angina Questionnaire (SAQ) scores, despite the inclusion of a patient with unsuccessful CTO PCI who continued to report a high angina burden (six episodes daily). Improvements in dyspnea and general health status measures were not observed.3
Several features of ORBITA-CTO strengthen the credibility of these findings. The investigators achieved double blinding in a setting where masking is particularly challenging, given the prolonged and technically complex nature of CTO PCI. Withdrawal of antianginal therapy prior to randomization reduced confounding from background therapy and strengthened the inference that observed effects were attributable to CTO PCI. Capturing daily symptoms, both limited recall bias and provided insight into the trajectory of symptom improvement, providing insight into the trajectory of symptom improvement, not just whether symptoms improved, but when, how quickly, and to what extent.4,5 The use of Bayesian statistics reflected a thoughtful approach in a modestly sized trial, showing a high likelihood that PCI conferred a meaningful reduction in angina.3,6
The design of ORBITA-CTO was structured to isolate the effect of CTO PCI by removing the two largest sources of confounding that have limited prior trials, namely effects of background medical therapy and patient expectations. Through withdrawal of antianginal medications and use of a sham-controlled design, the trial asked a narrowly focused, but fundamental, question: what effect does CTO PCI itself have on symptom relief? This is not how CTO PCI is applied in clinical practice, where PCI is layered onto background medical therapy, and patients are aware of the outcome. This was, however, the intention of the trial design. Earlier randomized CTO trials were unable to isolate the effect of CTO PCI from the benefits of medical therapy and bystander PCI, and could not account for patient expectations given the absence of a sham arm.7–10 In this context, ORBITA-CTO did not aim to redefine clinical strategy but rather answer the fundamental question of whether CTO PCI has a direct physiological effect at all.
The findings from ORBITA-CTO help define the scope of benefit. As in ORBITA-2, a proportion of patients continued to report symptoms after CTO PCI; and while angina and physical limitation improved, dyspnea and measures of overall health status did not. This likely reflects the multifactorial nature of symptoms in patients with chronic coronary syndromes.
Understanding how the results of ORBITA-CTO can inform clinical practice requires measured analysis. The investigators intentionally enrolled a highly selected population of patients without significant non-CTO disease, with evidence of ischemia, low-to-moderate lesion complexity CTOs (J-CTO ≤3), and procedures performed by experienced CTO operators who achieved high success rates. While this limits the generalizability of these findings for both patients and referring clinicians, the data provide rigorous evidence that CTO PCI confers a symptomatic benefit.
For CTO operators, the findings largely validate what has long been observed in practice, but now with a level of methodological rigor that prior studies lacked.
The ORBITA-CTO trial provides the most substantial evidence that CTO PCI reduces angina. At the same time, it underscores that this benefit is neither universal nor absolute. Thus, ORBITA-CTO serves less as a directive for clinical decision-making and more as proof of concept upon which clinical strategy can be built. The question is no longer whether CTO PCI can relieve symptoms, but rather determining which patients are most likely to derive a benefit.